Media releases
- May
- 10-May-2012 New data among 200 Lucentis® abstracts at ARVO show low number of injections with Novartis drug required to achieve and maintain vision gains over 3 years in AMD and DME patients »
- 07-May-2012 Novartis drug pasireotide LAR shows superior efficacy compared to Sandostatin® LAR® in Phase III trial of patients with acromegaly »
- 02-May-2012 Sandoz to acquire Fougera Pharmaceuticals, becoming the number one generic dermatology medicines company globally and in the US »
- 01-May-2012 Recent publicly-funded CATT trial highlights serious safety concerns around unlicensed ocular bevacizumab use versus Lucentis »
- April
- 26-Apr-2012 Novartis drug Afinitor® approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC »
- 26-Apr-2012 More than 25,000 Novartis associates worldwide to volunteer for local causes in Community Partnership Day »
- 25-Apr-2012 Novartis drug Signifor® approved in the EU as the first medication to treat patients with Cushing's disease »
- 24-Apr-2012 Pharmaceuticals and Alcon performed strongly in the first quarter; overall Group results impacted by expected challenges »
- 20-Apr-2012 Novartis drug Jakavi(TM) recommended by CHMP for EU approval to treat patients with the life-threatening blood cancer myelofibrosis »
- 20-Apr-2012 Novartis updates US label on Gilenya® following discussions with the FDA »
- 20-Apr-2012 Novartis confirms positive benefit-risk profile of Gilenya® following CHMP review and label update recommendation »
- 19-Apr-2012 Novartis announces Aliskiren will continue to be available to appropriate patients, as FDA interim assessment is concluded; product information updated »
- 19-Apr-2012 New extension study data with Novartis drug Gilenya® shows patients successfully treated for up to 7 years in relapsing MS »
- 02-Apr-2012 Novartis QVA149 Phase III COPD studies meet primary endpoints »
- March
- 28-Mar-2012 Novartis launches the Cancer Cell Line Encyclopedia (CCLE) to catalogue world's cancer cell lines »
- 27-Mar-2012 Study in JAMA reports significant survival benefit in certain GIST patients taking Novartis drug Glivec® for three years after surgery »
- 16-Mar-2012 Alcon gains exclusive ex-US rights for ocriplasmin, potential first pharmacological treatment for symptomatic vitreomacular adhesion »
- 07-Mar-2012 Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study »
- February
- 29-Feb-2012 Brian McNamara Named Division Head, Novartis OTC »
- 29-Feb-2012 Two Phase III studies of Novartis drug INC424 published in NEJM show significant clinical benefit for patients with myelofibrosis »
- 27-Feb-2012 European Commission approves new label for Novartis drug Glivec® extending adjuvant therapy to three years for certain GIST patients »
- 23-Feb-2012 Shareholders approve all proposed resolutions of Novartis Board of Directors »
- 17-Feb-2012 Novartis to revise product information in the European Union for high blood pressure drug Rasilez® following assessment by CHMP »
- 13-Feb-2012 FDA requests additional data on Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for expanded use in infants and toddlers »
- 07-Feb-2012 Pivotal study published in JAMA confirms potential of Novartis candidate vaccine Bexsero® to help protect infants against devastating meningococcal serogroup B disease »
- 01-Feb-2012 FDA approves Novartis drug Glivec® label recommending extending treatment to three years for certain GIST patients after surgery »
- January
- 30-Jan-2012 Novartis extends commitment to help achieve final elimination of leprosy »
- 25-Jan-2012 Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011 »
- 20-Jan-2012 CHMP recommends EU approval to update Novartis drug Glivec® label to include three year treatment for GIST patients after surgery »
- 20-Jan-2012 Novartis drug Signifor® recommended by CHMP for EU approval to treat patients with Cushing's disease »
- 19-Jan-2012 Sandoz initiates two more Phase III biosimilar trials, reinforcing long-term global leadership commitment »
- 18-Jan-2012 Novartis receives approval for Lucentis® and launches Galvus® in China, two innovative therapies that support public health goals »
- 13-Jan-2012 Novartis to restructure US business to strengthen competitive position in light of loss of Diovan® patent and announces charge for Rasilez®/Tekturna® »
- 08-Jan-2012 Novartis Consumer Health Inc. voluntarily recalls certain over-the-counter products in the US while Novartis Group strengthens quality standards across all manufacturing sites »
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
